Gaucher’s Disease Market Report 2026

Gaucher’s Disease Market Overview

• Gaucher’s Disease market size has reached to $1.76 billion in 2025 • Expected to grow to $2.32 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Prevalence Of Genetic Abnormalities Boost Gaucher Disease • Market Trend: Increasing Focus On Technological Advancements To Drive The Revenues • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Gaucher’s Disease Market?

Gaucher's disease is a rare genetic disorder that interferes with the metabolism of a particular kind of fat called glucocerebroside. This disorder is caused by the formation of a fatty substance called glucocerebroside within certain cells, particularly in the spleen, liver, bone marrow, and sometimes in the brain. The main types of Gaucher’s disease are Gaucher disease type 1, Gaucher disease type 2, Gaucher disease type 3, and others. Gaucher disease type 1 is the most common form of Gaucher disease and is characterized by a deficiency of the enzyme glucocerebrosidase. The various diagnoses include physical exams, blood tests, imaging tests, preconception screening and prenatal testing, and others. It can be treated by including enzyme replacement therapy and substrate reduction therapy, which can be administered through oral, parenteral, and other routes by various end users such as hospitals, specialty clinics, homecare, and others.

What Is The Gaucher’s Disease Market Growth Forecast?

The gaucher’s disease market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to development of next-generation therapies, expansion of newborn screening, increased access to rare disease treatments, growth in personalized medicine, improved patient survival. Major trends in the forecast period include rising adoption of enzyme replacement therapy, increased focus on early genetic diagnosis, expansion of substrate reduction therapies, growing awareness of rare genetic disorders, improved long-term disease management.

Global Gaucher’s Disease Market Segmentation

1) By Type: Gaucher Disease Type 1, Gaucher Disease Type 2, Gaucher Disease Type 3, Other Types 2) By Diagnosis: Physical Exam, Blood Tests, Imaging Tests, Preconception Screening And Prenatal Testing, Other Diagnoses 3) By Therapy: Enzyme Replacement Therapy, Substrate Reduction Therapy 4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 5) By End User: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegments: 1) By Gaucher Disease Type 1: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT) 2) By Gaucher Disease Type 2: Supportive Care, Experimental Therapies 3) By Gaucher Disease Type 3: Enzyme Replacement Therapy (ERT), Symptomatic Management 4) By Other Types: Rare Variants Of Gaucher Disease, Related Syndromes

What Is The Driver Of The Gaucher’s Disease Market?

The rising prevalence of genetic abnormalities is expected to propel the growth of the Gaucher's disease market going forward. Genetic abnormalities are changes or mutations that occur in the DNA sequence of a person's genes and may result in abnormal features, functions, or characteristics. The inheritance pattern of Gaucher's disease is autosomal recessive, which means that an individual must inherit two copies of the mutated GBA gene, one from each parent, to develop the disease. People with Gaucher's disease do not make enough of this enzyme, which leads to a buildup of fatty substances called lipids in certain organs such as the spleen and liver. For instance, in 2023 according to the Cystic Fibrosis Foundation, a US-based non-profit organization, the total population with Cystic Fibrosis without lung transplant in 2022 was 31,171 which increased to 31,752 in 2023. Therefore, the rising prevalence of genetic abnormalities is driving the growth of the Gaucher's disease market.

Key Players In The Global Gaucher’s Disease Market

Major companies operating in the gaucher’s disease market are Pfizer Inc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Sanofi S.A., BioMarin Pharmaceutical Inc., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Protalix BioTherapeutics, AVROBIO Inc., REGENXBIO Inc., Orphazyme A/S, Freeline Therapeutics Holdings plc, CANbridge Life Sciences Ltd, Sangamo Therapeutics Inc, Sigilon Therapeutics Inc, Spur Therapeutics, BioArctic AB, Horizon Therapeutics plc, ERAD Therapeutic, M6P Therapeutics, Lysogene

Global Gaucher’s Disease Market Trends and Insights

Major companies operating in the Gaucher's disease market are developing innovative technologies such as NGS (next-generation sequencing) to better serve the patients. Next-generation sequencing (NGS), also known as high-throughput sequencing, is a revolutionary technology that allows rapid and cost-effective sequencing of DNA and RNA molecules. For instance, in February 2023, Eurofins Genomics LLC, a US-based biotechnology company, launched a whole plasmid sequencing service utilizing advanced Gen3 NGS (next-generation sequencing) technology. This revolutionary offering delivers rapid, same-day results with impressive single-base accuracy of up to 99%. By strategically combining the strengths of Sanger sequencing's accuracy and quick turnaround time with the comprehensive analysis capabilities of NGS, the whole plasmid sequencing service bridges the gap between these two methods. This service accommodates long DNA constructs from 2.5 to 300 kb. With this new approach, Eurofins Genomics US empowers researchers with a cost-effective, time-efficient solution for long-read sequencing, offering a unique blend of accuracy and speed in the realm of genetic analysis.

What Are Latest Mergers And Acquisitions In The Gaucher’s Disease Market?

In May 2025, WuXi Biologics, a China‑based contract research, development, and manufacturing organization (CRDMO), partnered with CANbridge Pharmaceuticals, a biopharmaceutical company, to support the development and manufacturing of velaglucerase‑beta (Gaurunning), which received approval from China’s NMPA for Gaucher disease. With this collaboration, WuXi Biologics leverages its manufacturing and biologics expertise to help CANbridge scale production of this enzyme‑replacement therapy, enabling broader access to treatment within the Gaucher patient population. CANbridge Pharmaceuticals is a China‑based biotech firm specializing in novel therapies for rare diseases, notably Gaucher disease.

Regional Outlook

North America was the largest region in the Gaucher's disease market in 2025. Europe is expected to be the fastest growing region in the forecast period. The regions covered in the gaucher’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gaucher’s disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gaucher’s Disease Market?

The gaucher's disease market includes revenues earned by entities by providing services such as genetic counseling, patient education and support, research and clinical trials, and pain management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The gaucher's disease market consists of sales of bone health supplements, medical equipment, and diagnostic testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gaucher’s Disease Market Report 2026?

The gaucher’s disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gaucher’s disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.